Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
This study intends to explore the efficacy and safety of PD-L1 inhibitor Adebrelimab combined with the CDK4/6 inhibitor Dalpcicilib and standard endocrine therapy given as neoadjuvant treatment in stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Breast Cancer|HR+/HER2- Breast Cancer
DRUG: Adebrelimab+Dalpciclib+Standard Endocrine Therapy
tpCR rate, Total pathologic complete response (tpCR) rate, defined as ypT0/is, ypN0 as assessed by investigator., through study completion, an average of one and a half years
OS, OS is defined as the time between enrollment and the patient\&#39;s death due to any cause., up to 3 years|EFS, Event-Free Survival (EFS) is defined as the time from firest dose to disease progression, disease recurrence, or death, whichever comes first., up to 3 years|Ki67, Evaluation by a pathologist by manual counting according to WHO 2017 recommendations, Baseline and At Surgery|ORR, Objective response rate(ORR) is defined as the proportion of patients with complete response(CR) and partial response(PR) assessed by the investigator in accordance with the RECIST 1.1 criteria., Baseline up to Cycle 5（each cycle is 28 days）
This single-center, open-label, single-arm clinical trial aims to evaluate the efficacy and safety of the neoadjuvant treatment with the PD-L1 inhibitor Adebrelimab in combination with the CDK4/6 inhibitor Dalpicicilib in combination with standard endocrine therapy, for stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.